Emergent Health Corp
EMGE
Other OTC0.00
USD
- -
- -
CIK
0001463459
ISIN
US29100Q3083
CUSIP
29100Q308
Return %
Stock
S&P500
1Y
-50.00
26.84
3Y
-96.15
77.03
5Y
-99.82
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James W. Zimbler
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10120 Valley Forge Circle King of Prussia PA United States of America 19406
- IPO Date
- Sep 8, 2009
- CIK
- 0001463459
- Website
- emergenthealthcorp.com
- Similar Companies
- Business
- Emergent Health Corp is a company engaged in developing, manufacturing, and marketing products in the regenerative health sector, specializing in regenerative medicine, nutraceuticals, and phytonutritionals. Its core product portfolio includes Vita-Stim, which enhances the immune system and nourishes stem cells; Neuvitale, a methyl donor protecting DNA; Hungarest, a diet aid controlling appetite; EmergentO2, a water oxygenator that increases oxygen in the bloodstream; and products aimed at reducing facial wrinkles. The company distributes these products primarily through e-commerce and influencer marketing channels, targeting health-conscious consumers seeking innovative regenerative health solutions. Emergent Health operates across the United States with headquarters in New York, and through subsidiaries such as Evolutionary Biologics, it leverages proprietary technologies for product development and FDA-compliant manufacturing. In recent major developments, Emergent Health completed the acquisition of Nanosthetic Cosmetic Labs in early 2023, which added approximately $3.5 million in revenue and expanded the company's capabilities with sterile processing technologies for biologics. Additionally, it signed a Letter of Intent to acquire a profitable regenerative medical company specializing in osteoarthritis treatment and platelet-rich plasma (P.R.P.) therapies, with current revenues of $5.4 million and projected revenues of $9 million for 2023. This acquisition is expected to enhance clinical reach with a large sales force exceeding 300 representatives and the largest osteoarthritis treatment network in the U.S. Emergent also launched the MAXIMUS Men's Health vertical targeting regenerative health solutions for men’s aging challenges, reflecting a strategic expansion into specialized health markets. The company is led by CEO Jim Morrison, former L’Oréal president, who focuses on transparency and shareholder value through regular updates and strategic growth. Emergent Health’s business segments include regenerative medicine, biologic product development, nutraceuticals, and cosmetic health products. The company targets consumers looking for immune system enhancement, stem cell nourishment, weight management, and anti-aging therapies. Its recent acquisitions and product launches position it for significant revenue growth from both direct consumer sales and expansion into professional medical networks. Founded in 2009 and headquartered in New York, Emergent Health operates mainly in the U.S. market but plans growth through innovation and strategic mergers within the regenerative health ecosystem. This comprehensive profile captures Emergent Health Corp’s detailed product offerings, recent strategic acquisitions, business focus, and operational geography, reflecting a dynamic and expanding player in the regenerative health industry.
Apollo Biowellness, Inc./Resonate Blends, Inc., Provides Corporate Update Following Closing of Share Exchange Agreement
Resonate Blends Executes a Share Exchange Agreement With Emergent Health Corp.